Table 2.

RCTs Reporting Histological Outcomes in People With NASH Treated With Pioglitazone

Study	n	Pioglitazone Dose, mg/day	Patients With Type 2 Diabetes, %	Duration, weeks	Patients With NASH Resolution, %*	People With Fibrosis Improvement, %*
Belfort et al. (29)	55	45	42	24	Not reported†	13
Aithal et al. (30)	74	30	0	50	Not reported†	9
Sanyal et al. (32)	247	30	0	96	26‡	13
Cusi et al. (31)	101	45	51	72	32‡	14
Bril et al. (34)	105	45 + vitamin E	100	72	31‡	22
Huang et al. (33)	90	30	23	24	16	1

^*Resolution of NASH and fibrosis improvement are rounded, placebo-subtracted data.

^†Histological data are not reported as NASH resolution; improved necroinflammation (Belfort et al. [29]): 47%; improved hepatocellular injury (Aithal et al. [30]): 22%.

^‡Significant vs. placebo.